Innovaderm continues to focus on the well-being and safety of our employees and patients, supporting business continuity for us and our customers, and ensuring that our studies continue to be conducted in compliance with applicable regulations.


Innovaderm continues to follow Health Canada, regional authorities, and Centers for Disease Control (CDC) guidance. Following the latest announcement by the Quebec Government prolonging the requirement that all nonessential businesses close their offices to facilitate the enforcement of social distancing until further notice, our headquarters offices are closed since March 24, 2020.


There is currently no interruption in Innovaderm CRO services. All employees are working remotely during this period. Public transit, air and rail travel are discouraged, and face-to-face meetings are being replaced with teleconferences or video conferences.


Innovaderm is collaborating with vendors and sites on active trials to apply their COVID-19 business continuity plan, while maintaining oversight on quality and data integrity of ongoing studies. Innovaderm will remain nimble and adapt to new regulatory requirements and monitoring resourcing strategies as required, in consultation with Sponsor, IRB and Regulatory Authorities.


Innovaderm will continue to review our business continuity plan and adjust as needed. Further updates and information about Innovaderm’s response to COVID-19 will be shared on this webpage.



For COVID-19 criteria, visit the following websites:


Health Canada:
Notice to clinical trial sponsors

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic

Health Canada:


EMA Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic